Advertisement

Journal of Endocrinological Investigation

, Volume 22, Issue 6, pp 486–492 | Cite as

Sildenafil and erectile dysfunction

  • A. Fabbri
  • A. Aversa
  • A. Isidori
Opinion

Key-words

Sildenafil phosphodiesterase inhibitors impotence therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    NIH Consensus Conference. Impotence. J. Am. Med. Ass. 1993, 270: 83–90.CrossRefGoogle Scholar
  2. 2.
    Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., McKinlay J.B. Impotence and its medical and psychological correlates: results of the Massachusetts male aging study. J. Urol. 1994, 151: 54–61.PubMedGoogle Scholar
  3. 3.
    Lugg J.A., Gonzales-Cadavid N.F., Rajfer J. The role of nitric oxide in erectile function. J. Androl. 1995, 16: 2–4.PubMedGoogle Scholar
  4. 4.
    Fabbri A., Aversa A., Isidori A. Erectile dysfunction: an overview. Hum. Reprod. Update 1997, 3: 455–466.PubMedCrossRefGoogle Scholar
  5. 5.
    Heaton J.P.W., Adams M.A., Morales A. A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative. Int. J. Impot. Res. 1997, 9: 115–121.PubMedCrossRefGoogle Scholar
  6. 6.
    Ballard S.A., Burslem F.M.F., Gingell C.J.C., Price M.E., Tang K., Turner L.A., Naylor A.M. In vitro profile of UK-92-480, an inhibitor of cyclic GMP-specific phosphodiesterase 5 for the treatment of male erectile dysfunction. J. Urol. 155 (Suppl.) 1996, 676A, (Abst) 1462.Google Scholar
  7. 7.
    Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H., Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor in the treatment of penile erectile dysfunction. Int. J. Impot. Res. 1996, 8: 47–52.PubMedGoogle Scholar
  8. 8.
    Ballard S.A., Gingell C.J., Tang K., Turner L.A., Price M.E., Naylor A.M. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. 1998, 159: 2164–2171.PubMedCrossRefGoogle Scholar
  9. 9.
    Hultling C., Giuliano F., Quirk F., Peña B., Mishra A., Smith M., and The Sildenafil Study Group. Effect of sildenafil (Viagra) on quality of life in men with erectile dysfunction (ED) caused by traumatic spinal cord injury (SCI). Int. J. Impot. Res. 1998, 10 (Suppl. 3), 532.Google Scholar
  10. 10.
    Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wcker P.A. Oral Sildenafil in the treatment of erectile dysfunction. N. Engl. J. Med. 1998, 338: 1397–1404.PubMedCrossRefGoogle Scholar
  11. 11.
    Morales A., Gingell C., Collins M., Wicker P.A., Osterloh I. Clinical safety of oral sildenafil citrate (Viagra™) in the treatment of erectile dysfunction. Int. J. Impot. Res. 1998, 10: 69–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Chuang A.T., Strauss J.D., Murphy R.A., Steers W.D. Sildenafil, a type-5 phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J. Urol. 1998, 160: 257–261.PubMedCrossRefGoogle Scholar
  13. 13.
    Soderling S.H., Bayuga S.J., Beavo J.A. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J. Biol. Chem. 1998, 273: 15553–15558.PubMedCrossRefGoogle Scholar
  14. 14.
    Stief C.G., Uckert S., Becker A.J., Truss M.C., Jonas U. The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. J. Urol. 1998, 159: 1390–1393.PubMedCrossRefGoogle Scholar
  15. 15.
    Feenstra J., van Drie-Pierik R.J.H.M., Laclè C.F., Stricker B.H.Ch. Acute myocardial infarction associated with sildenafil. Lancet 1998, 352: 957–958.PubMedCrossRefGoogle Scholar
  16. 16.
    Wagner G., Saenz de Tejada I. Update on male erectile dysfunction. Br. Med. J. 1998, 316: 678–682.CrossRefGoogle Scholar
  17. 17.
    Mills T.M., Reilly C.M., Lewis R.W. Androgens and penile erection: a review. J. Androl. 1996, 17: 633–638.PubMedGoogle Scholar
  18. 18.
    Aversa A., Bertucci B., Bonifacio V., Isidori A., Fabbri A. Dynamic color-Doppler Sonography in male erectile dysfunction: re-dosing with phentolamine plus prostaglandin-E1 to maximize erectile response. In: Meuleman E., Lycklama à Nijeholt G., Vanderschueren D. (Eds.), The 8th World Meeting on Impotence Research, Amsterdam, The Netherlands. Monduzzi Editore, Bologna, 1998, p. 215–218.Google Scholar
  19. 19.
    Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J. Urol. 1996, 155: 802–815.PubMedCrossRefGoogle Scholar
  20. 20.
    Heaton J.P.W., Adams M.A., Morales A., Hassouna M., Brock G., Mc Gill U., Shao Sigh R., Lue T.F., El Rasnioly R. Apomorphine SL is effective in the treatment of non-organic erectile dysfunction: results of a multicenter trial. Int. J. Impot. Res. 1996, 8: 109, (Abs) #A64.Google Scholar
  21. 21.
    Becker A.J., Stief C.G., Machtens S., Schulteiss D., Hartmann U., Truss M.C., Jonas U. Oral phentolamine as treatment for erectile dysfunction. J. Urol. 1998, 159: 1214–1215.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1999

Authors and Affiliations

  1. 1.Cattedra di Andrologia, Dipartimento di Fisiopatologia MedicaUniversità “La Sapienza”RomeItaly

Personalised recommendations